


## Puerarin

Cat. No.:	HY-N0145	
CAS No.:	3681-99-0	
Molecular Formula:	C <sub>21</sub> H <sub>20</sub> O <sub>9</sub>	
Molecular Weight:	416.38	
Target:	5-HT Receptor	
Pathway:	GPCR/G Protein; Neuronal Signaling	
Storage:	Powder	-20°C 3 years
		4°C 2 years
	In solvent	-80°C 6 months
		-20°C 1 month



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (120.08 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.4017 mL	12.0083 mL	24.0165 mL
		5 mM	0.4803 mL	2.4017 mL	4.8033 mL
10 mM		0.2402 mL	1.2008 mL	2.4017 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 3 mg/mL (7.20 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 3 mg/mL (7.20 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 3 mg/mL (7.20 mM); Suspended solution; Need ultrasonic				
	4. Add each solvent one by one: 20% SBE-β-CD in saline Solubility: 20 mg/mL (48.03 mM); Clear solution; Need ultrasonic				

### BIOLOGICAL ACTIVITY

Description	Puerarin, an isoflavone extracted from Radix puerariae, is a 5-HT <sub>2C</sub> receptor antagonist.
IC <sub>50</sub> & Target	5-HT <sub>2C</sub> Receptor
In Vitro	Puerarin inhibits the expression of LPS-induced iNOS, COX-2 and CRP proteins and also suppresses their mRNAs from RT-

PCR experiments in RAW264.7 cells. The inhibition of iNOS, COX-2 and CRP expression is due to a dose-dependent inhibition of phosphorylation and degradation of I- $\kappa$ B, which resulted in the reduction of p65NF- $\kappa$ B nuclear translocation. The effect of puerarin-mediated inhibition of LPS-induced iNOS, COX-2 and CRP expression is attributed to suppressed NF- $\kappa$ B activation at the transcriptional level<sup>[1]</sup>. Puerarin is a novel open-channel blocker of IK1, which may underlie the antiarrhythmic action of puerarin. Puerarin competes with barium, an open-channel blocker of IK1, to inhibit IK1 currents<sup>[2]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

Both genistein and puerarin effectively alleviate hepatic damage induced by chronic alcohol administration through potential antioxidant, anti-inflammatory, or anti apoptotic mechanisms. However, genistein is more effective than puerarin in decreasing levels of malondialdehyde (1.05±0.0947 vs. 1.28±0.213 nmol/mg pro, p < 0.05), tumor necrosis factor  $\alpha$  (3.12±0.498 vs. 3.82±0.277 pg/mg pro, p < 0.05), interleukin-6 (1.46±0.223 vs. 1.88±0.309 pg/mg pro, p < 0.05), whereas puerarin is more effective than genistein in ameliorating serum activities or levels of alanine transaminase (35.8±3.95 vs. 42.6±6.56 U/L, p < 0.05) and low-density lipoprotein cholesterol (1.12±0.160 vs. 1.55±0.150 mmol/L, p < 0.05)<sup>[3]</sup>. Early-stage renal damages can be significantly improved by puerarin, possibly via its suppression of ICAM-1 and TNF- $\alpha$  expression in diabetic rat kidneys<sup>[4]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

#### Cell Assay<sup>[1]</sup>

RAW264.7 cells are maintained at subconfluence in 95% air and 5% CO<sub>2</sub> humidified atmosphere maintained at 37°C. The medium used for routine subculture is Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum, penicillin (100 units/mL) and streptomycin (100  $\mu$ g/mL). An MTT assay is used to measure the viability of the cells after treatment with puerarin. After the supernatants are removed for nitrite determination, cells are incubated at 37°C with MTT (0.05 mg/mL) for 4 h, and the optical density is measured at 540 nm. The concentrations of puerarin are 10, 20, 40 and 100  $\mu$ M<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### Animal Administration<sup>[3][4]</sup>

**Rats:** A cohort of healthy male SD rats (7 weeks old) are randomly divided into a control group, a model group, and a puerarin treatment group with high (H), moderate (M), and low (L) dosage. Puerarin is re-suspended in 0.9% saline and is given by intra-gastric intubation at various concentrations (0.25 mg/(kg×d) for L group, 0.5 mg/(kg×d) for M group, and 1.0 mg/(kg×d) for H group) each day for 8 consecutive days. An equal volume of saline is administered to control and model rats during the same time period<sup>[4]</sup>.

**Mice:** Forty male ICR mice (weight: 20-22 g) are acclimatized with a daily 12 h light:12 h dark cycle at 22±2 °C room temperature and 55%±5% relative humidity. After 1 week of adaption, the mice are randomly divided into four groups with ten mice per group. Genistein and puerarin are applied to the mice in sodium carboxymethyl cellulose solution with an equimolar concentration of 0.1 M (gastric volume: 3 mL kg<sup>-1</sup> body weight)<sup>[3]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Acta Pharm Sin B. 2020 Jul.
- Mol Med Rep. 2019 Apr;19(4):2876-2882.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- 
- [1]. Hu W, et al. Puerarin inhibits iNOS, COX-2 and CRP expression via suppression of NF- $\kappa$ B activation in LPS-induced RAW264.7 macrophage cells. *Pharmacol Rep.* 2011;63(3):781-9.
- [2]. Zhang H, et al. Puerarin: a novel antagonist to inward rectifier potassium channel (IK1). *Mol Cell Biochem.* 2011 Jun;352(1-2):117-23.
- [3]. Zhao L, et al. Protective Effects of Genistein and Puerarin against Chronic Alcohol-Induced Liver Injury in Mice via Antioxidant, Anti-inflammatory, and Anti-apoptotic Mechanisms. *J Agric Food Chem.* 2016 Sep 28;64(38):7291-7.
- [4]. Pan X, et al. Effect of Puerarin on Expression of ICAM-1 and TNF- $\alpha$  in Kidneys of Diabetic Rats. *Med Sci Monit.* 2015 Jul 23;21:2134-40.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA